Such classification proves very important in management, as those subtypes differ in pathophysiology and may require different treatments, e.g., thymectomy is recommended in AChR-MG of early onset but not in AChR-MG of late onset; anticholinesterases are less effective and may even worsen MuSK-MG, etc. The expected approval of biologicals targeting specific steps in pathophysiology (antibody production, complement action) stressed the need to distinguish the subtypes further. This evidence concerns the gene MUSK and myasthenia gravis.